DiscoveryProbe™ FDA-approved Drug Library: Empowering High-Throughput Drug Repositioning and Target Identification

Introduction: Principle and Setup of the DiscoveryProbe™ FDA-approved Drug Library

Drug discovery is being revolutionized by ready-to-use compound libraries, and the DiscoveryProbe™ FDA-approved Drug Library stands at the forefront of this transformation. Comprising 2,320 clinically approved bioactive compounds, this FDA-approved bioactive compound library is meticulously curated to enable high-throughput screening (HTS), high-content screening (HCS), and rapid pharmacological target identification. The compounds—spanning receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators—are provided as stable 10 mM DMSO solutions, ready for immediate screening.

Key features that differentiate this high-throughput screening drug library include:

• Comprehensive Coverage: Compounds are FDA-, EMA-, HMA-, CFDA-, and PMDA-approved or pharmacopeia-listed, ensuring global regulatory relevance.
• Ready-to-Screen Convenience: Pre-dissolved solutions in multiple plate formats (96-well, deep well, and 2D barcoded tubes) streamline setup.
• Stability and Reliability: Solutions remain stable for 12 months at -20°C and up to 24 months at -80°C, minimizing variability across experiments.
• Mechanistic Diversity: Encompasses a wide range of mechanisms, making it ideal for drug repositioning screening and signal pathway regulation studies.

Whether investigating cancer, neurodegenerative diseases, or rare pathologies, the DiscoveryProbe™ library offers a robust starting point for translational breakthroughs.

Step-by-Step Experimental Workflow: Enhancing Screening and Discovery

1. Plate Preparation and Compound Handling

The library's compounds arrive in DMSO at 10 mM; before screening, allow plates to equilibrate to room temperature to avoid condensation. Briefly centrifuge to collect any condensation and ensure homogeneity. Avoid repeated freeze-thaw cycles by aliquoting as needed.

2. Assay Setup for High-Throughput or High-Content Screening

• Cell Seeding: Plate target cells (e.g., C2C12 myoblasts for muscle studies, cancer cell lines for oncology) at optimal density in assay plates.
• Compound Addition: Using a multichannel pipette or automated liquid handler, transfer compounds to wells. For dose–response, perform serial dilutions directly in assay plates.
• Controls: Include DMSO-only, positive control (reference drug), and negative control (untreated) wells for assay normalization.

3. Assay Readout and Data Acquisition

Depending on the study (e.g., viability, transcriptional reporter, enzymatic activity, signal pathway modulation), readouts may include fluorescence, luminescence, or imaging endpoints. For example, the recent sarcopenia study leveraged a PHF20-YY1 promoter luciferase assay to identify sulfasalazine as a potent inhibitor of muscle atrophy signaling, demonstrating the practical impact of systematic screening.

4. Data Analysis

Normalize assay signals to controls, calculate Z'-factors (ideally >0.5 for robust screens), and apply hit selection criteria (e.g., >3 standard deviations from mean, or IC₅₀ estimation through nonlinear regression). Export results for bioinformatics, pathway analysis, or follow-up validation.

Advanced Applications and Comparative Advantages

Drug Repositioning: From Bench to Bedside

The DiscoveryProbe™ FDA-approved Drug Library is uniquely suited for drug repositioning screening, enabling rapid identification of new indications for existing drugs. In the sarcopenia study (Park et al., 2025), sulfasalazine—originally an anti-inflammatory for IBD—was repurposed as a modulator of PHF20/YY1 signaling, with significant effects in mouse models and clinical cohorts. This approach accelerates translational pipelines by leveraging known safety profiles and pharmacokinetics.

Target Identification and Mechanism Discovery

By encompassing diverse pharmacological classes, researchers can dissect complex signaling pathways, identify off-target effects, and map compound-target interactions. The library's proven utility in cancer research drug screening and neurodegenerative disease drug discovery is further illustrated in published resources:

• DiscoveryProbe FDA-approved Drug Library: Accelerating Drug Repositioning and Target Discovery complements this article by detailing how the compound collection streamlines workflows from mechanism-based screens to in vivo validation.
• Transforming High-Content Screening extends the discussion with case studies on rare and complex disease models, highlighting the library's versatility in both high-content and mechanistic discovery settings.
• From Mechanistic Insight to Precision Therapy offers strategic guidance for bridging early discovery to clinical application, illustrating the library's role in translational innovation.

Together, these resources form a comprehensive view of how this high-content screening compound collection is reshaping modern pharmacology.

Quantified Performance and Success Metrics

• Screening Efficiency: 2,320 pre-dissolved compounds reduce hands-on time by 40–60% compared to dry powder libraries.
• Hit Rate: Studies report primary hit rates of 0.5–3%, with follow-up confirmation rates exceeding 70% due to high compound purity and stability.
• Data Robustness: Z'-factors typically range from 0.65–0.85 in optimized cell-based assays, indicating excellent assay quality.

Troubleshooting and Optimization Tips

Common Challenges and Solutions

• DMSO Effects: Maintain final DMSO concentration below 0.5% in cell-based assays to minimize toxicity. Validate cell tolerance with a DMSO gradient if uncertain.
• Compound Precipitation: If precipitation is observed (rare due to DMSO solubility), briefly vortex and centrifuge. For stubborn cases, warm to 37°C prior to use and inspect visually.
• Edge Effects in Plates: Use plate sealers and avoid placing critical samples in outer wells. Pre-equilibrate plates before adding cells to minimize evaporation-related artifacts.
• Freeze-Thaw Stability: Aliquot compounds post-thaw if repeated use is anticipated; limit to ≤5 freeze-thaw cycles to preserve integrity.
• Pipetting Accuracy: Calibrate multichannel pipettes regularly, and use low-retention tips to prevent compound loss—especially for viscous DMSO stocks.

Protocol Enhancements

• Integrate automation (liquid handling robots) for large-scale screens to enhance reproducibility and throughput.
• Apply high-content imaging for multiparametric phenotypic readouts, enabling detection of subtle morphological or signaling changes.
• Leverage informatics tools for hit clustering and pathway enrichment to rapidly contextualize results and prioritize follow-up.

Future Outlook: Expanding Horizons with DiscoveryProbe™

As drug repositioning and precision medicine accelerate, compound libraries like DiscoveryProbe™ will be pivotal for the next wave of discoveries. Integration with CRISPR screens, omics data, and AI-based hit triage is on the horizon, promising even more powerful insights across cancer, neurodegeneration, and emerging infectious diseases. The library’s unparalleled stability, clinical relevance, and workflow compatibility make it a cornerstone for future high-throughput and high-content screening initiatives.

For researchers aiming to maximize the impact of their experimental designs, the DiscoveryProbe™ FDA-approved Drug Library offers a proven, versatile platform—whether the goal is drug repositioning, target identification, or unlocking new frontiers in biomedical research.